[go: up one dir, main page]

WO2002030469A3 - Efficacite therapeutique amelioree de complexe beta-lactamine/polysaccharide - Google Patents

Efficacite therapeutique amelioree de complexe beta-lactamine/polysaccharide Download PDF

Info

Publication number
WO2002030469A3
WO2002030469A3 PCT/IN2001/000179 IN0100179W WO0230469A3 WO 2002030469 A3 WO2002030469 A3 WO 2002030469A3 IN 0100179 W IN0100179 W IN 0100179W WO 0230469 A3 WO0230469 A3 WO 0230469A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
lactam
lactam antibiotic
polysaccharide complex
antibiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2001/000179
Other languages
English (en)
Other versions
WO2002030469A2 (fr
Inventor
Prasanta Kumar Chakrabarti
Canakapalli Bhaktavatsala Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orchid Pharma Ltd
Original Assignee
Orchid Chemicals and Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals and Pharmaceuticals Ltd filed Critical Orchid Chemicals and Pharmaceuticals Ltd
Priority to AU2002215180A priority Critical patent/AU2002215180A1/en
Publication of WO2002030469A2 publication Critical patent/WO2002030469A2/fr
Publication of WO2002030469A3 publication Critical patent/WO2002030469A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

L'invention concerne un type de complexe bêta-lactamine/polysaccharide présentant une dose moins élevée de fraction active, ce qui permet de maintenir la réponse pharmacologique et microbiologique par rapport au médicament mère respectif, tout en réduisant la toxicité et le coût du traitement. L'invention concerne également un procédé relatif à l'élaboration de bêta-lactamines, qui consiste à faire réagir un antibiotique à noyau bêta-lactame avec des polysaccharides en présence d'un solvant, et à lyophiliser le complexe résultant sous vide.
PCT/IN2001/000179 2000-10-12 2001-10-11 Efficacite therapeutique amelioree de complexe beta-lactamine/polysaccharide Ceased WO2002030469A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002215180A AU2002215180A1 (en) 2000-10-12 2001-10-11 Beta-lactam antibiotic-polysaccharide complex

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN730/MAS/1999 2000-10-12
IN729MA1999 2000-10-12
IN730MA1999 2000-10-12
IN729/MAS/1999 2000-10-12

Publications (2)

Publication Number Publication Date
WO2002030469A2 WO2002030469A2 (fr) 2002-04-18
WO2002030469A3 true WO2002030469A3 (fr) 2003-02-27

Family

ID=26324828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2001/000179 Ceased WO2002030469A2 (fr) 2000-10-12 2001-10-11 Efficacite therapeutique amelioree de complexe beta-lactamine/polysaccharide

Country Status (2)

Country Link
AU (1) AU2002215180A1 (fr)
WO (1) WO2002030469A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025783A2 (fr) * 2011-08-15 2013-02-21 Gentle Thomas M Composition antimicrobienne soluble dans l'eau
US8815952B1 (en) 2013-03-15 2014-08-26 Carnell & Herzog, LLC Chlorhexadine antiseptic
CN104382864A (zh) * 2014-08-29 2015-03-04 四川制药制剂有限公司 注射用头孢曲松钠的加工工艺
CN106279208A (zh) * 2016-08-15 2017-01-04 陕西顿斯制药有限公司 一种利用流体力学原理制备的头孢噻肟钠化合物及其制剂
CN113842365B (zh) * 2021-10-28 2022-10-28 海南海灵化学制药有限公司 一种注射用头孢唑林钠的制备工艺

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489065A (en) * 1981-07-02 1984-12-18 Valcor Scientific Ltd. Chondroitin drug Complexes
WO1992017167A1 (fr) * 1991-04-02 1992-10-15 Biotech Australia Pty. Ltd. Systemes de liberation orale de microparticules
WO1998016253A1 (fr) * 1996-10-15 1998-04-23 Ebara Corporation Produit polymere bioactif
WO1999015150A1 (fr) * 1997-09-22 1999-04-01 Buford Biomedical, Inc. Complexes inorganiques-polymeres utiles pour une liberation controlee de composes comprenant des composes medicinaux
WO2000078287A1 (fr) * 1999-05-18 2000-12-28 Istituto Biochimico Pavese Pharma S.P.A. Produits d'addition polymeres a base de polysaccharides naturels antibiotiques
WO2001097851A2 (fr) * 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions et methodes visant a ameliorer l'absorption orale d'agents anti-microbiens

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489065A (en) * 1981-07-02 1984-12-18 Valcor Scientific Ltd. Chondroitin drug Complexes
WO1992017167A1 (fr) * 1991-04-02 1992-10-15 Biotech Australia Pty. Ltd. Systemes de liberation orale de microparticules
WO1998016253A1 (fr) * 1996-10-15 1998-04-23 Ebara Corporation Produit polymere bioactif
WO1999015150A1 (fr) * 1997-09-22 1999-04-01 Buford Biomedical, Inc. Complexes inorganiques-polymeres utiles pour une liberation controlee de composes comprenant des composes medicinaux
WO2000078287A1 (fr) * 1999-05-18 2000-12-28 Istituto Biochimico Pavese Pharma S.P.A. Produits d'addition polymeres a base de polysaccharides naturels antibiotiques
WO2001097851A2 (fr) * 2000-06-21 2001-12-27 Cubist Pharmaceuticals, Inc. Compositions et methodes visant a ameliorer l'absorption orale d'agents anti-microbiens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLTENI L.: "Dextran and inulin conjugates as drug carriers.", METHODS IN ENZYMOLOGY, (1985) VOL. 112/- (285-298). CODEN: MENZAU, XP008004814 *

Also Published As

Publication number Publication date
AU2002215180A1 (en) 2002-04-22
WO2002030469A2 (fr) 2002-04-18

Similar Documents

Publication Publication Date Title
CA2148928A1 (fr) Derives pyridine pharmacologiquement actifs ainsi que leurs procedes de preparation
CA2123363A1 (fr) Conjugues de medicaments antitumoraux clivables et d'enzymes lysosomiaux
HK1046527A1 (zh) 金剛烷衍生物
GEP20032967B (en) Indolyl-3-Glyoxylic Acid Derivatives As an Antitumor Agent and Pharmaceutical Composition
WO2004041153A3 (fr) Composition pharmaceutique comprenant de faibles dosages de desmopressine
WO2001046200A8 (fr) Nouveaux derives de piperidine et de piperazine
CA2386775A1 (fr) Medicaments de traitement de tumeurs malignes
CA2127111A1 (fr) Une methode pour preparer des medicaments oraux enrobes a delitage enterique renfermant des composes instables en milieu acide
CA2362760A1 (fr) Derives de camptothecine ayant une action antitumorale
AU2003273413A1 (en) Pharmaceutically active oligosaccharide conjugates
CA2189328A1 (fr) Compositions de tocopherol destinees a l'apport d'agents biologiquement actifs
HUT62466A (en) Process for producing locally applicable pharmaceutical compositions comprising allylamine derivatives, against fungus infection
IL117091A0 (en) Methylphenyloxazolidinone derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
MX9803692A (es) Derivados de eritromicina triciclicos.
DE602004011966D1 (en) Heterocyclylverbindungen
HUT56849A (en) Process for producing antibiotic complexes and chelates and pharmaceutical compositions comprising such active ingredient
AU4459297A (en) Glycoconjugates from modified camptothecin derivates (20-o-linkage)
EP0388956A3 (fr) Dérivé de phtalinide, composition pharmaceutique et utilisation
WO2002030469A3 (fr) Efficacite therapeutique amelioree de complexe beta-lactamine/polysaccharide
CA2123367A1 (fr) Composition pharmaceutique anti-allergique pour administration ophtalmique topique
NO177714C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive peptidderivater
WO2001002407A3 (fr) Derives de taxane et procedes de preparation de ceux-ci
CA2176144A1 (fr) Derives d'anthracycline pour le traitement des amyloses
IL129616A0 (en) Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
WO2001030391A3 (fr) Composition pharmaceutique contenant du midazolam

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)